Immunovant, Inc.

Listed Company

IMVTCIK 0001764013NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Mar 31

Period

FY 2026

Revenue

—

Net Income

$-505.61M

Total Assets

$957.01M

Equity

$852.59M

Shares Out

205.31M

Op. Cash Flow

$-407.31M

Business

Immunovant, Inc. is a clinical-stage immunology company developing IMVT-1402, a next-generation fully human anti-FcRn monoclonal antibody, and advancing its first-generation candidate, batoclimab, to treat IgG-mediated autoimmune diseases. Its main products and services include IMVT-1402 and batoclimab development programs, clinical trials across multiple indications, and delivery via a subcutaneous autoinjector formulation. The company organizes its pipeline by therapeutic areas—endocrinology, neurology, rheumatology and dermatology—with potentially registrational trials in Graves’ disease, MG, CIDP, D2T RA, Sjögren’s and CLE. It pursues development and commercialization primarily across the Licensed Territory (U.S., Canada, Mexico, E.U., U.K., Switzerland, Middle East, North Africa and Latin America), relies on contract manufacturing organizations for production and plans a targeted U.S. specialty sales organization and strategic collaborations for distribution.

Summary from filing dated 2025-05-29

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Operating expenses:	—	—	—
Research and development	457	361	213
Acquired in-process research and development	0	0	13
General and administrative	76	77	57
Total operating expenses	533	438	283
Interest income, net	25	25	25
Other (income) expense, net	2	471,000	−1
Loss before provision for income taxes	−505	−413	−259
Provision for income taxes	215,000	891,000	567,000
Net loss	−506	−414	−259
Net loss per common share — basic (in dollars per share)	−2.77	−2.73	−1.88
Net loss per common share — diluted (in dollars per share)	−2.77	−2.73	−1.88
Weighted average common shares outstanding — basic (in shares)	182	152	138
Weighted average common shares outstanding — diluted (in shares)	182	152	138

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31
Assets	—	—
Current assets:	—	—
Cash and cash equivalents	902	714
Accounts receivable	1	2
Prepaid expenses and other current assets	43	51
Income tax receivable	3	427,000
Total current assets	949	768
Operating lease right-of-use assets	72,000	98,000
Property and equipment, net	443,000	844,000
Other assets	8	8
Total assets	957	776
Liabilities and Stockholders’ Equity	—	—
Current liabilities:	—	—
Accounts payable	8	18
Accrued expenses	97	51
Current portion of operating lease liabilities	72,000	98,000
Due to Roivant Sciences Ltd.	175,000	273,000
Total current liabilities	104	69
Total liabilities	104	69
Commitments and contingencies (Note 10)	—	—
Stockholders’ equity:	—	—
Preferred stock	0	0
Common stock, par value $0.0001 per share, 500,000,000 shares authorized, 203,940,353 shares issued and outstanding at March 31, 2026 and 500,000,000 shares authorized, 170,111,593 shares issued and outstanding at March 31, 2025	20,000	16,000
Additional paid-in capital	2,597	1,945
Accumulated other comprehensive income	730,000	1
Accumulated deficit	−1,745	−1,240
Total stockholders’ equity	853	707
Total liabilities and stockholders’ equity	957	776

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Mar 31, 2026 2026-03-31	Mar 31, 2025 2025-03-31	Mar 31, 2024 2024-03-31
Cash flows from operating activities	—	—	—
Net loss	−506	−414	−259
Adjustments to reconcile net loss to net cash used in operating activities:	—	—	—
Stock-based compensation	56	49	41
Depreciation on property and equipment	409,000	377,000	231,000
Non-cash lease expense	99,000	133,000	1
Changes in operating assets and liabilities:	—	—	—
Accounts receivable	−986,000	−3	5
Prepaid expenses and other current assets	−9	27	−2
Income tax receivable	2	261,000	−19,000
Other assets	−69,000	8	0
Accounts payable	−10	11	6
Accrued expenses	45	9	1
Operating lease liabilities	−99,000	−138,000	−1
Due to Roivant Sciences Ltd.	−98,000	255,000	−329,000
Net cash used in operating activities	−407	−376	−214
Cash flows from investing activities	—	—	—
Purchases of property and equipment	8,000	759,000	360,000
Net cash used in investing activities	−8,000	−759,000	−360,000
Cash flows from financing activities	—	—	—
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement	544	450	473
Payment of offering and private placement costs	504,000	319,000	6
Proceeds from stock options exercised	52	5	6
Net cash provided by financing activities	596	454	472
Effect of exchange rate changes on cash and cash equivalents	−299,000	747,000	993,000
Net change in cash and cash equivalents	188	79	259
Cash and cash equivalents – end of period	—	—	—
Cash and cash equivalents – end of period	—	—	—
Non-cash operating activity	—	—	—
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	73,000	98,000	91,000
Supplemental disclosure of cash paid:	—	—	—
Income taxes	2	1	509,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro